{"publication_id":"a2d1bd44-d221-428e-b691-ad49f3c24335","traces":[{"claim_id":"claim_1","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction","doi":"10.1111/acel.12194","url":"https://pubmed.ncbi.nlm.nih.gov/24472261/"},{"study":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice","doi":"10.1038/nature08221","url":"https://pubmed.ncbi.nlm.nih.gov/19587680/"},{"study":"Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer","doi":"10.1111/acel.12496","url":"https://pubmed.ncbi.nlm.nih.gov/27312235/"},{"study":"Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice","doi":"10.7554/eLife.16351","url":"https://pubmed.ncbi.nlm.nih.gov/27549339/"},{"study":"The Mechanistic Target of Rapamycin (mTOR) Pathway as a Target of Anti-aging Therapies: The Role of Rapamycin and Its Analogs in the Regulation of Cellular Processes and Their Impact on Longevity.","doi":"10.7759/cureus.98514","url":"https://pubmed.ncbi.nlm.nih.gov/41497909/"}]},{"claim_id":"claim_2","claim":"_No direct opposing receipt was selected by this run. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._","candidate_sources":[{"study":"Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction","doi":"10.1111/acel.12194","url":"https://pubmed.ncbi.nlm.nih.gov/24472261/"},{"study":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice","doi":"10.1038/nature08221","url":"https://pubmed.ncbi.nlm.nih.gov/19587680/"},{"study":"Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer","doi":"10.1111/acel.12496","url":"https://pubmed.ncbi.nlm.nih.gov/27312235/"},{"study":"Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice","doi":"10.7554/eLife.16351","url":"https://pubmed.ncbi.nlm.nih.gov/27549339/"},{"study":"The Mechanistic Target of Rapamycin (mTOR) Pathway as a Target of Anti-aging Therapies: The Role of Rapamycin and Its Analogs in the Regulation of Cellular Processes and Their Impact on Longevity.","doi":"10.7759/cureus.98514","url":"https://pubmed.ncbi.nlm.nih.gov/41497909/"}]}]}